{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:51:01Z","timestamp":1760147461001,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: In patients with mantle cell lymphoma (MCL), long-term remissions can be achieved by stem cell transplantation (SCT). Different conditioning treatment protocols exist with or without total body irradiation (TBI). There are few data published on the role of TBI before autologous stem cell transplantation (autoSCT) or allogenic stem cell transplantation (alloSCT). We report on the long-term survival data of patients treated by TBI prior to autologous or allogenic SCT at our center. Patients: In a retrospective analysis, the data of patients treated at the University Hospital of Muenster from May 2004 to February 2015 were collected and evaluated. For the analysis, all data of patients who were histopathologically diagnosed with MCL and underwent TBI prior to stem cell transplantation (SCT) were evaluated. Results: A total of 22 patients (19 men and 3 women) were treated with a TBI-based conditioning prior to SCT. The median age at initial diagnosis was 57.5 years (38\u201365 years). Seventeen patients had Ann Arbor stage IV, two patients had Ann Arbor stage III, and three patients Ann Arbor stage II disease. AutoSCT was performed in 19 patients and alloSCT was performed in 3 patients. In 18 patients, autoSCT was applied as part of first-line therapy, and in one patient after relapse. Two patients received alloSCT after relapse of MCL, and one patient received alloSCT during first-line therapy after an inadequate treatment response. TBI was performed in 12 patients with 10 Gy and in 6 patients with 12 Gy, these patients subsequently received autoSCT. In the group of four patients who received TBI with four Gy, four patients subsequently received alloSCT and one patient received autoSCT. Median overall survival after autoSCT and previous TBI was 11.4 years (142 months). In total, 11 out of 19 patients treated with autoSCT lived longer than 6.8 years (82\u2013202 months). After alloSCT and previous TBI, the median overall survival was 3.25 years (14\u201359 months). Conclusions: A large proportion of patients with advanced MCL survived remarkably longer than 11.4 years after high-dose chemotherapy, TBI, and SCT. The present results of multimodal treatment support the published reports that TBI-based high-dose therapy followed by autoSCT is highly effective in this prognostically unfavorable disease situation.<\/jats:p>","DOI":"10.3390\/cancers15030983","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:29:05Z","timestamp":1675661345000},"page":"983","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-0524","authenticated-orcid":false,"given":"Kai","family":"Kr\u00f6ger","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Siats","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Hematology and Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Hematology and Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Hematology and Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-5986","authenticated-orcid":false,"given":"Gabriele","family":"Reinartz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer Campus 1, Building 1A, 48419 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.14694\/EdBook_AM.2014.34.191","article-title":"Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches","volume":"34","author":"Dreyling","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell Lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma\u2014Advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022\u2014A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.18.00690","article-title":"Survival Outcomes of Younger Patients with Mantle Cell Lymphoma Treated in the Rituximab Era","volume":"37","author":"Gerson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V114.22.880.880","article-title":"Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma","volume":"114","author":"Hoster","year":"2009","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41409-022-01596-8","article-title":"Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study","volume":"57","author":"Hueso","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20406207221080744","DOI":"10.1177\/20406207221080743","article-title":"Mantle cell lymphoma management trends and novel agents: Where are we going?","volume":"13","author":"Pu","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: A post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2019-127863","article-title":"Triangle: Autologous Transplantation after a Rituximab\/Ibrutinib\/ara-c Containing Induction in Generalized Mantle Cell Lymphoma\u2014A Randomized European MCL Network Trial","volume":"134","author":"Dreyling","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"EVIDoa2100001","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"720","article-title":"Uber Bestrahlungen des ganzen menschlichen K\u00f6rpers bei Blutkrankheiten","volume":"26","author":"Teschendorf","year":"1925","journal-title":"Strahlentherapie"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transpl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0360-3016(94)00335-I","article-title":"Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia","volume":"31","author":"Dusenbery","year":"1995","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m2 melphalan and 8 Gy total body irradiation plus 140 mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study","volume":"39","author":"Peters","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbmt.2017.10.029","article-title":"Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biol. Blood Marrow Transplant","volume":"24","author":"Tseng","year":"2018","journal-title":"J. Am. Soc. Blood Marrow Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/983\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:23:30Z","timestamp":1760120610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15030983"],"URL":"https:\/\/doi.org\/10.3390\/cancers15030983","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}